Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (15334)	2/19/1998 2:03:00 PM
From: Henry Niman	Respond to of 32384

Bernie, The street is clueless. LGND's deal with LLY was very comprehensive. It included PPARs, HNF4, and the leptin promoter program and will target much more than diabetes. LLY needs to build a pipeline. Initial Evista sales were disappointing and the stock has been pounded. I expect LLY to jump into these programs with both feet. Diabetes trials will take the lead in the clinic, but much will go on at the pre-clinical level to develop additional blockbusters. The street has trouble counting past 1 or 2 or looking beyond the next quarter's results. Long term investors should take advantage of the street's preoccupation with short term results.